Provided by Tiger Trade Technology Pte. Ltd.

Soligenix, Inc.

1.65
+0.02001.23%
Volume:356.83K
Turnover:581.73K
Market Cap:16.64M
PE:-0.39
High:1.70
Open:1.63
Low:1.56
Close:1.63
52wk High:6.23
52wk Low:1.09
Shares:10.09M
Float Shares:7.93M
Volume Ratio:0.87
T/O Rate:4.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.2455
EPS(LYR):-4.9786
ROE:-165.10%
ROA:-69.38%
PB:2.19
PE(LYR):-0.33

Loading ...

Soligenix Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Stockholders' Equity Requirement

Reuters
·
Aug 16

Soligenix Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 14

Soligenix Q2 EPS $(0.82) Beats $(0.92) Estimate

Benzinga
·
Aug 14

Soligenix Inc. Reports No Revenue and Increased Net Loss of $2.7 Million in Q2 2025 with EPS of ($0.82)

Reuters
·
Aug 14

Soligenix Announces Recent Accomplishments and Second Quarter 2025 Financial Results

THOMSON REUTERS
·
Aug 14

Press Release: Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

Dow Jones
·
Aug 14

Networknewsaudio Announces Audio Press Release (Apr) on Promising First-Line Therapy for Rare Skin Cancer

THOMSON REUTERS
·
Aug 08

Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy

GlobeNewswire
·
Aug 07

Soligenix Inc. Unveils Corporate Presentation Highlighting Advances in Rare Disease Treatments and Significant Commercial Opportunities

Reuters
·
Aug 06

Soligenix Inc expected to post a loss of 92 cents a share - Earnings Preview

Reuters
·
Aug 05

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

GlobeNewswire
·
Aug 05

Crude Oil Falls 1%; Meta Earnings Top Views

Benzinga
·
Aug 01

Soligenix Inc. Announces Successful Phase 2 Trial Results for SGX945 in Treating Behçet's Disease

Reuters
·
Jul 31

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of Sgx945 for the Treatment of BehÇEt's Disease

THOMSON REUTERS
·
Jul 31

Soligenix Inc - Sgx945 Well-Tolerated With No Adverse Events

THOMSON REUTERS
·
Jul 31

Soligenix Inc. Announces Enrollment Progress in Phase 3 FLASH2 Trial for HyBryte™ in Cutaneous T-cell Lymphoma

Reuters
·
Jul 08

Soligenix Inc. Partners with Sterling Pharma Solutions for U.S. Manufacturing of Synthetic Hypericin

Reuters
·
Jul 01

Soligenix Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 21